Neurogene director granted 12,050 stock options
Neurogene Inc. director Keith Woods received a fully vested non-qualified stock option grant.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4/A
Rhea-AI Filing Summary
Neurogene Inc. director Keith Woods received a fully vested non-qualified stock option grant. The award covers 12,050 options, each giving the right to buy one share of common stock at an exercise price of $20.40 per share, expiring on June 12, 2035. Following this compensation-related grant, Woods holds 12,050 derivative securities directly, with no open-market share purchases or sales reported in this filing.
Insider Trade Summary
Grant/Award: 12,050 shares
Grant/Award
1 txn
Insider
Woods Keith
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 12,050 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 12,050 contracts (Direct)
Holdings Before and After:
Non-Qualified Stock Option (right to buy), 0 to 12,050 contracts (Direct)
Footnotes (1)
- F1. This option is fully vested.
Key Figures
Options granted: 12,050 options
Exercise price: $20.40 per share
Expiration date: June 12, 2035
+2 more
5 metrics
Options granted
12,050 options
Non-qualified stock option grant to director Keith Woods
Exercise price
$20.40 per share
Exercise price for the 12,050 options
Expiration date
June 12, 2035
Option expiration for the grant
Holdings after transaction
12,050 derivative securities
Total options held directly after grant
Transaction date
June 12, 2025
Date of option grant
Key Terms
Non-Qualified Stock Option, exercise price, fully vested, derivative securities, +1 more
5 terms
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
exercise price financial
"conversion_or_exercise_price: 20.4000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fully vested financial
"This option is fully vested."
derivative securities financial
"total_shares_following_transaction: 12050.0000"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
Form 4/A regulatory
"form_type: "4/A""
Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Neurogene (NGNE) report for Keith Woods?
Neurogene reported a grant of 12,050 fully vested non-qualified stock options to director Keith Woods. Each option allows him to buy one common share at a $20.40 exercise price, with the grant treated as compensation rather than an open-market trade.
How many Neurogene (NGNE) options did Keith Woods receive in this Form 4/A?
Keith Woods received 12,050 non-qualified stock options in this Form 4/A. The options are fully vested and each is exercisable into one share of Neurogene common stock, giving him rights over 12,050 underlying shares at a fixed exercise price.
What is the exercise price of Keith Woods’ Neurogene (NGNE) stock options?
The exercise price of Keith Woods’ Neurogene stock options is $20.40 per share. This means he can choose to buy Neurogene common stock at $20.40 for each of the 12,050 options granted, any time before the options expire in 2035.
When do Keith Woods’ Neurogene (NGNE) stock options expire?
Keith Woods’ non-qualified stock options expire on June 12, 2035. Up to that date, he may exercise up to 12,050 options to purchase Neurogene common shares at the fixed $20.40 exercise price, subject to his personal decisions and market conditions.
Are Keith Woods’ Neurogene (NGNE) options from this filing already vested?
Yes, the filing states that the option grant to Keith Woods is fully vested. This means all 12,050 options are immediately exercisable at the $20.40 per-share exercise price, without any additional service or performance conditions required for vesting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
